VistaGen Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
VistaGen Therapeutics, Inc. carries a market capitalization of 7.70M, placing it among publicly traded companies globally. Its enterprise value stands at -23.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.70M |
| Enterprise Value | -23.42M |
Share Statistics
VistaGen Therapeutics, Inc. currently has 39.62M shares outstanding.
| Shares Outstanding | 39.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 16.49, and the price-to-book ratio stands at -0.04.
| PE Ratio | N/A |
| PS Ratio | 16.49 |
| PB Ratio | -0.04 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | -0.32 |
| P/OCF Ratio | -0.32 |
Enterprise Valuation
| EV / Sales | 76.27 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
VistaGen Therapeutics, Inc. maintains a current ratio of 3.67, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.67 |
| Quick Ratio | 3.55 |
| Debt / Equity | 2.94 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -104.86 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 7,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
VistaGen Therapeutics, Inc.'s stock has declined approximately -90.74803% over the past 52 weeks. The 50-day moving average sits at 0.51, while the 200-day moving average is 1.53.
| Beta (5Y) | N/A |
| 52-Week Price Change | -90.74803% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 1.53 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, VistaGen Therapeutics, Inc. generated 1.27M in revenue and converted that into -69.68M in net income, yielding earnings per share of -1.90. EBITDA reached -71.39M, while operating income came in at -72.12M.
| Revenue | 1.27M |
| Gross Profit | N/A |
| Operating Income | -72.12M |
| Pretax Income | -69.68M |
| Net Income | -69.68M |
| EBITDA | -71.39M |
| EBIT | -72.12M |
| Earnings Per Share (EPS) | -1.90 |
Balance Sheet
VistaGen Therapeutics, Inc. holds 45.40M in cash and equivalents against 1.04M in total debt, resulting in a net debt position of -30.69M. Total book value stands at -477.28M, with working capital of 34.15M providing operational flexibility.
| Cash & Cash Equivalents | 45.40M |
| Total Debt | 1.04M |
| Net Debt | -30.69M |
| Equity (Book Value) | -477.28M |
| Book Value Per Share | -13.03 |
| Working Capital | 34.15M |
Cash Flow
VistaGen Therapeutics, Inc. produced -66.44M in operating cash flow over the past twelve months. After subtracting -151,000.00 in capital expenditures, free cash flow totaled -66.59M - equivalent to -1.82 per share.
| Operating Cash Flow | -66.44M |
| Capital Expenditures | -151,000.00 |
| Free Cash Flow | -66.59M |
| FCF Per Share | -1.82 |
Margins
VistaGen Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -5,678.74 and net profit margin of -5,487.01 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -5,678.74 |
| Pretax Margin | -5,486.46 |
| Profit Margin | -5,487.01 |
| EBITDA Margin | -5,621.02 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -147.91 |
| FCF Yield | -316.57 |
Stock Splits
VistaGen Therapeutics, Inc.'s most recent stock split took place on June 7, 2023 with a 30:1 split ratio.
| Last Split Date | 6/7/2023 |
| Split Ratio | 30:1 |
Scores
VistaGen Therapeutics, Inc. posts an Altman Z-Score of -16.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -16.83 |